MedTrace Logo

AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

NCT06911333 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-04-04

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or metastatic solid tumors. The main questions it aims to answer are:

* Which dosage of AD1208 is safe and tolerable for participants?
* What medical problems do participants have when taking AD1208?

Participants will:

* Take drug AD1208 every day up to 1 cycle at the least.
* Visit the site once every 1 weeks for checkups and tests during cycle 1 and every 3 weeks from cycle 2 onwards.
* Keep a diary of any adverse events and administrated drug

Conditions

  • Solid Tumor, Adult
  • Tumor, Solid
  • Solid Tumor
  • Solid Tumor, Unspecified, Adult
  • Solid Tumor Cancer
  • Solid Tumors Refractory to Standard Therapy
  • Solid Tumor in Advanced Stage

Interventions

DRUG

AD1208

Up to 6 of cohorts will be applied sequentially in phase Ia part.

Sponsors & Collaborators

  • Avelos Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-11
Primary Completion
2029-06-30
Completion
2030-02-20

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06911333 on ClinicalTrials.gov